Enliven Therapeutics initiates coverage with overweight rating and $75 target price
ELVN•JPMorgan initiated coverage of Enliven Therapeutics with an overweight rating and a $75 target price.
Related News
Press digest: Wall Street Journal stories for October 1
PSKY•
Gaming and Leisure Properties Inc.: RBC cuts target price to $44 from $52
GLPI•
Treasury's smaller-than-expected buybacks fuel debate over aims
TLT•
Platinum Group affiliate advances platinum, palladium lithium-sulfur cells to pilot-scale prototypes
PLG•
Getty Realty Corp.: RBC cuts target price to $30 from $36
GTY•